Lifecore Biomedical (NAS:LFCR) Interest Coverage

: 0 (At Loss) (As of May. 2023)

View and export this data going back to 1996. Start your Free Trial

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Lifecore Biomedical's Operating Income for the three months ended in May. 2023 was $-5.4 Mil. Lifecore Biomedical's Interest Expense for the three months ended in May. 2023 was $-4.5 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Lifecore Biomedical's Interest Coverage or its related term are showing as below:

LFCR's Interest Coverage is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 13.15
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Lifecore Biomedical Interest Coverage Historical Data

The historical data trend for Lifecore Biomedical's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Lifecore Biomedical Annual Data

Trend

May14

May15

May16

May17

May18

May19

May20

May21

May22

May23

Interest Coverage

1.43

0.52

Lifecore Biomedical Quarterly Data
	Aug18	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23
Interest Coverage																-	-	-	-	-

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Lifecore Biomedical's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lifecore Biomedical Interest Coverage Distribution

For the Drug Manufacturers industry and Healthcare sector, Lifecore Biomedical's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Lifecore Biomedical's Interest Coverage falls into.

Lifecore Biomedical Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Lifecore Biomedical's Interest Coverage for the fiscal year that ended in May. 2023 is calculated as

Here, for the fiscal year that ended in May. 2023, Lifecore Biomedical's Interest Expense was $-18.2 Mil. Its Operating Income was $-24.0 Mil. And its Long-Term Debt & Capital Lease Obligation was $111.0 Mil.

Lifecore Biomedical did not have earnings to cover the interest expense.

Lifecore Biomedical's Interest Coverage for the quarter that ended in May. 2023 is calculated as

Here, for the three months ended in May. 2023, Lifecore Biomedical's Interest Expense was $-4.5 Mil. Its Operating Income was $-5.4 Mil. And its Long-Term Debt & Capital Lease Obligation was $111.0 Mil.

Lifecore Biomedical did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's Financial Strength is.

Lifecore Biomedical (NAS:LFCR) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

Lifecore Biomedical Interest Coverage Related Terms

Thank you for viewing the detailed overview of Lifecore Biomedical's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

Lifecore Biomedical (NAS:LFCR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lifecore Biomedical Inc (NAS:LFCR) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

LDE:Germany

Address

3515 Lyman Boulevard, Chaska, MN, USA, 55318

Website

https://www.lifecore.com

Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid.

Executives

Legion Partners, L.p. Ii	director	12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, L.p. I	director	12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners Asset Management, Llc	director	12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Christopher S Kiper	director	12121 WILSHIRE BLVD, SUITE 1240, LOS ANGELES CA 90025
Raymond T. White	director	12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, Llc	director	12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners Holdings, Llc	director	12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Nathaniel Calloway	director	C/O ANEBULO PHARMACEUTICALS, INC., 1415 RANCH ROAD 620 SOUTH, SUITE 201, LAKEWAY TX 78734
Raymond H Diradoorian	director	C/O LANDEC CORPORATION, 2811 AIRPARK DRIVE, SANTA MARIA CA 93455
Wynnefield Capital Management Llc	10 percent owner	450 SEVENTH AVE, STE 509, NEW YORK NY 10123
Wynnefield Small Cap Value Offshore Fund Ltd	10 percent owner	450 SEVENTH AVE, STE 509, NEW YORK NY 10123
Wynnefield Capital Inc	10 percent owner	450 SEVENTH AVE, STE 509, NEW YORK NY 10123
Wynnefield Capital, Inc. Profit Sharing Plan	10 percent owner	450 SEVENTH AVENUE, SUITE 509, NEW YORK NY 10123
Joshua Landes	10 percent owner
Wynnefield Partners Small Cap Value Lp I	10 percent owner	450 SEVENTH AVENUE, SUITE 509, NEW YORK NY 10123